Department of medicine
Few centers in the Southeast offer this procedure, and the national allocation system does not typically prioritize patients with colorectal metastases — meaning extended waits on the transplantation list for these patient populations.
UAB researchers review how senescent “zombie” cells contribute to skeletal muscle weakness with aging and disease, outlining emerging therapies such as senolytics and senomorphics that could help preserve muscle health and extend health span.
The transplant offers a new treatment option for the more than 18,500 Americans yearly who are diagnosed with blood cancers and need a bone marrow transplant.
UAB researchers demonstrated that GLP-1 receptor agonist use is associated with a lower risk of heart failure, dangerous heart rhythms and major cardiovascular events in patients with non-obstructive hypertrophic cardiomyopathy.
The collaborative project was selected from a rigorous pool of 400 letters of intent and 87 applications, with the Birmingham Veterans Affairs team being the only VA-funded awardee.
New clinical services and specialty programs are expanding access to high-quality care in Birmingham and throughout Alabama.
By integrating new collaborative relationships and cutting-edge technologies UAB transplant teams are helping to redefine what is possible in organ utilization and patient outcomes.
A rise in research funding within UAB’s Department of Family and Community Medicine highlights its expanding research impact.
UAB experts say there are many steps people can take to minimize the impacts of a sedentary lifestyle on their heart health.
Patients who received the additional therapy showed a higher likelihood of surviving at both one month and three months after treatment.
New research from UAB shows a structured expert panel approach can accurately and reliably measure delirium severity in patients with and without Alzheimer’s disease and related dementias.
UAB has been a national leader in Fabry disease care and research for more than two decades.
Cardiovascular disease is the second leading cause of death among cancer survivors, second only to cancer itself
More than 9,400 people are on the waiting list for a liver transplant in the United States. UAB’s new living-donor liver transplant program aims to help that number decrease.
UAB scientists discovered an oral drug stopped weight rebound after discontinuation or cessation of GLP‑1 treatment in preclinical studies, opening the door to a new approach for maintaining weight loss.
The MajesTEC-3 clinical trial shows that using a new two-drug immunotherapy regimen can lead to long-lasting remission for patients with multiple myeloma. Over 83 percent of patients enrolled in the trial are alive and progression-free three years after therapy.
Martin Young, Ph.D., says moving the clocks ahead one hour in March is associated with a 10 percent to 24 percent increase in the risk of having a heart attack the following Monday.
In February 2026, UAB performed its first NKR-facilitated transplants, opening a new era of expanded donor options beyond the program’s historically internal swap and chain database.
A new UAB and Alabama CEAL initiative aims to improve health by empowering neighborhoods.
In a study published in the New England Journal of Medicine, long-acting injectables proved to be a more effective treatment in maintaining consistent administration for those living with HIV and facing barriers to taking daily oral medications.